Form 4: Akoya Biosciences CEO Brian McKelligon Executes Stock Option and Sells Shares
SEC Form 4 Filing
Akoya Biosciences' CEO, Brian McKelligon, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 20, 2024, Brian McKelligon, the President and CEO of Akoya Biosciences, Inc., exercised an option to purchase 7,500 shares of common stock at a price of $0.303 per share.
- Simultaneously, McKelligon sold 7,500 shares of common stock at a weighted average price of $4.9657 per share, with individual sales prices ranging from $4.855 to $5.08.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 16, 2023.
- Following these transactions, McKelligon directly owns 231,868 shares of Akoya Biosciences common stock and holds options to purchase 290,629 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions and provides insight into the trading activity of Akoya Biosciences' CEO. It's common for executives to utilize 10b5-1 plans to manage their stock transactions and avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the CEO's stock sale, but the pre-arranged trading plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| August 16, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| March 20, 2024 | Date of stock option exercise and share sale |
| March 22, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.